Haesuk Park1, Ghadeer K Dawwas1, Xinyue Liu1, Mindie H Nguyen2. 1. From the, Department of Pharmaceutical Outcomes and Policy, University of Florida College of Pharmacy, Gainesville, FL, USA. 2. Division of Gastroenterology and Hepatology, Stanford University Medical Center, Palo Alto, CA, USA.
Abstract
BACKGROUND: As the prevalence of nonalcoholic fatty liver disease (NAFLD) escalates, understanding its potential impact on the development of chronic kidney disease (CKD) is needed. OBJECTIVE: To determine the longitudinal association of NAFLD with the development of advanced CKD in the United States. METHODS: A retrospective cohort analysis of the Truven Health MarketScan Database (2006-2015) was conducted. We used Cox proportional hazards models to compare the risk of developing CKD stages 3-5 in patients with NAFLD versus non-NAFLD, identified by ICD-9 codes, after 1:3 propensity score (PS) matching. RESULTS: In a cohort of 262 619 newly diagnosed patients with NAFLD and 769 878 PS (1:3)-matched non-NAFLD patients, we identified 5766 and 8655 new advanced (stage 3-5) CKD cases, respectively. The crude CKD incidence rate was 8.2 and 5.5 per 1000 person-years in NAFLD and non-NAFLD groups, respectively. In multivariable Cox model, patients with NAFLD had a 41% increased risk of developing advanced CKD compared with non-NAFLD patients [adjusted hazard ratio (aHR), 1.41; 95% confidence interval (CI), 1.36-1.46]. In the sensitivity analysis adjusting for time-varying covariates after NAFLD diagnosis, NAFLD persisted as a significant CKD risk factor (aHR, 1.58; 95% CI, 1.52-1.66) and the association remained significant when stratified by age, gender and pre-existing comorbidities. The risk of CKD increased in NAFLD with compensated cirrhosis (aHR, 1.47; 95% CI, 1.36-1.59) and decompensated cirrhosis (aHR, 2.28; 95% CI, 2.12-2.46). CONCLUSION: Nonalcoholic fatty liver disease was independently associated with an increased risk of advanced CKD development suggesting renal function screening and regular monitoring are needed in this population.
BACKGROUND: As the prevalence of nonalcoholic fatty liver disease (NAFLD) escalates, understanding its potential impact on the development of chronic kidney disease (CKD) is needed. OBJECTIVE: To determine the longitudinal association of NAFLD with the development of advanced CKD in the United States. METHODS: A retrospective cohort analysis of the Truven Health MarketScan Database (2006-2015) was conducted. We used Cox proportional hazards models to compare the risk of developing CKD stages 3-5 in patients with NAFLD versus non-NAFLD, identified by ICD-9 codes, after 1:3 propensity score (PS) matching. RESULTS: In a cohort of 262 619 newly diagnosed patients with NAFLD and 769 878 PS (1:3)-matched non-NAFLD patients, we identified 5766 and 8655 new advanced (stage 3-5) CKD cases, respectively. The crude CKD incidence rate was 8.2 and 5.5 per 1000 person-years in NAFLD and non-NAFLD groups, respectively. In multivariable Cox model, patients with NAFLD had a 41% increased risk of developing advanced CKD compared with non-NAFLD patients [adjusted hazard ratio (aHR), 1.41; 95% confidence interval (CI), 1.36-1.46]. In the sensitivity analysis adjusting for time-varying covariates after NAFLD diagnosis, NAFLD persisted as a significant CKD risk factor (aHR, 1.58; 95% CI, 1.52-1.66) and the association remained significant when stratified by age, gender and pre-existing comorbidities. The risk of CKD increased in NAFLD with compensated cirrhosis (aHR, 1.47; 95% CI, 1.36-1.59) and decompensated cirrhosis (aHR, 2.28; 95% CI, 2.12-2.46). CONCLUSION:Nonalcoholic fatty liver disease was independently associated with an increased risk of advanced CKD development suggesting renal function screening and regular monitoring are needed in this population.
Authors: Paul E Ronksley; Marcello Tonelli; Hude Quan; Braden J Manns; Matthew T James; Fiona M Clement; Susan Samuel; Robert R Quinn; Pietro Ravani; Sony S Brar; Brenda R Hemmelgarn Journal: Nephrol Dial Transplant Date: 2011-10-19 Impact factor: 5.992
Authors: M Alan Brookhart; Sebastian Schneeweiss; Kenneth J Rothman; Robert J Glynn; Jerry Avorn; Til Stürmer Journal: Am J Epidemiol Date: 2006-04-19 Impact factor: 4.897
Authors: E Vilar-Gomez; L Calzadilla-Bertot; S L Friedman; B Gra-Oramas; L Gonzalez-Fabian; O Villa-Jimenez; S Lazo-Del Vallin; M Diago; L A Adams; M Romero-Gomez; N Chalasani Journal: Aliment Pharmacol Ther Date: 2016-11-16 Impact factor: 8.171
Authors: Christopher D Williams; Joel Stengel; Michael I Asike; Dawn M Torres; Janet Shaw; Maricela Contreras; Cristy L Landt; Stephen A Harrison Journal: Gastroenterology Date: 2010-09-19 Impact factor: 22.682
Authors: Vincent L Chen; Ming-Lun Yeh; Ju Dong Yang; Jennifer Leong; Daniel Q Huang; Hidenori Toyoda; Yao-Li Chen; Jennifer Guy; Mayumi Maeda; Pei-Chien Tsai; Chung-Feng Huang; Satoshi Yasuda; An K Le; Hansen Dang; Nasra H Giama; Hamdi A Ali; Ning Zhang; Xiaozhong Wang; Dae Won Jun; Cheng-Hao Tseng; Yao-Chun Hsu; Jee-Fu Huang; Chia-Yen Dai; Wan-Long Chuang; Qiang Zhu; Yock Young Dan; Myron Schwartz; Lewis R Roberts; Ming-Lung Yu; Mindie H Nguyen Journal: Hepatol Commun Date: 2020-09-24